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Abstract
MicroRNAs are increasingly being recognized as regulators of embryonic development; however, relatively few microRNAs
have been identified to regulate cardiac development. FOG-2 (also known as zfpm2) is a transcriptional co-factor that we
have previously shown is critical for cardiac development. In this report, we demonstrate that FOG-2 expression is controlled
at the translational level by microRNA-130a. We identified a conserved region in the FOG-2 39 untranslated region predicted
to be a target for miR-130a. To test the functional significance of this site, we generated an expression construct containing
the luciferase coding region fused with the 39 untranslated region of FOG-2 or a mutant version lacking this microRNA
binding site. When these constructs were transfected into NIH 3T3 fibroblasts (which are known to express miR-130a), we
observed a 3.3-fold increase in translational efficiency when the microRNA target site was disrupted. Moreover, knockdown
of miR-130a in fibroblasts resulted in a 3.6-fold increase in translational efficiency. We also demonstrate that cardiomyocytes
express miR-130a and can attenuate translation of mRNAs with a FOG-2 39 untranslated region. Finally, we generated
transgenic mice with cardiomyocyte over-expression of miR-130a. In the hearts of these mice, FOG-2 protein levels were
reduced by as much as 80%. Histological analysis of transgenic embryos revealed ventricular wall hypoplasia and ventricular
septal defects, similar to that seen in FOG-2 deficient hearts. These results demonstrate the importance of miR-130a for the
regulation of FOG-2 protein expression and suggest that miR-130a may also play a role in the regulation of cardiac
development.
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Introduction
MicroRNAs (miRNAs) are ,22 nucleotide RNA molecules that
are emerging as important regulators of gene expression. First
describedinC.elegans,miRNAshavenowbeenidentifiedthroughout
theplantandanimalkingdoms[1,2,3,4].TheseRNAsaregenerated
fromaprimaryRNAtranscriptthroughthesequentialactionsofthe
RNase-III enzymes Drosha and Dicer before associating with
proteinsoftheRNA-inducedsilencingcomplex(RISC).MicroRNAs
havebeenshowntoinhibittranslationordecreasemRNAstabilityby
bindingtospecificsitesusuallyinthe39untranslatedregion(UTR)of
target messages, thus providing another layer of control of gene
expression[5,6,7,8].WhileinplantsmostmiRNAsdirectcleavageof
target mRNAs, most well characterized mammalian miRNA-target
interactions to date have been shown to result in translational
inhibition of the target [9].
Over 500 miRNAs have been cloned and sequenced, and for
many, their targets are unknown. Several computational algo-
rithms have been developed to predict miRNA target genes, but
only a few of these predictions have been validated [10,11].
Without detailed knowledge of miRNA targets, it is difficult to
predict their roles in development and disease. However, given the
ability of miRNAs to regulate protein translation, it is reasonable
to assume that miRNAs could be involved in the regulation of
these processes in vertebrates [12].
Cardiac development in mammals is a complex process that
involves the coordinated activity of a number of different
transcription factors and signaling molecules. For a number of
these factors, it is clear that the factor’s precise expression level is
critical for normal development. For example, just a 60%
reduction in Tbx20 protein expression during cardiac develop-
ment leads to cardiac malformations [13]. Thus, even two-fold
differences in critical transcriptional regulators may influence
heart formation and it is therefore reasonable to suggest that
miRNAs may play a role in regulating cardiac development.
Indeed, recent work has begun to elucidate the role of miRNAs
in cardiac development and disease. Cardiac-restricted deletion of
Dicer during early mouse embryogenesis led to embryonic
lethality due to cardiac malformations, while deletion later in
development led to an early post-natal lethality secondary to a
dilated cardiomyopathy [14,15]. MiR-1-2 has been shown to play
a critical role in cardiac morphogenesis, as mice deficient in miR-
1-2 die in utero of cardiac malformations [14]. Targeted deletion of
miR-208, while not leading to a developmental defect, blocked the
heart’s ability to develop a hypertrophic response to stress [16].
These examples are likely just the beginning of the roles of
miRNAs in cardiovascular development and disease that will be
identified [17].
FOG-2 (also known as zfpm2) is transcription factor that we have
previously shown to be required for cardiac development [18,19].
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functions as a transcriptional co-repressor by binding to the
transcriptional activator GATA-4 and modulating GATA-depen-
dent promoter activity [20,21,22]. Mice deficient in FOG-2 die in
mid-gestation of cardiac malformations that include ventricular
septal defects and ventricular wall hypoplasia [18,19]. In this
report, we describe the identification and characterization of an
evolutionary conserved target site in the 39 UTR of FOG-2 for
microRNA-130a (miR-130a). When coupled to a reporter, the
FOG-2 39 UTR inhibits translation over 3-fold in a cell line
expressing miR-130a. Mutation of the predicted miRNA target
site within the FOG-2 UTR or blocking miR-130a relieves this
translational inhibition. We show that miR-130a is expressed in
cardiomyocytes and when over-expressed during embryonic
development, results in a down-regulation of FOG-2 protein
levels and structural heart defects similar to those seen in mice
deficient in FOG-2, thus suggesting that it may play a role in
regulating cardiac development.
Results
MicroRNA-130a is expressed in the heart and is predicted
to target a conserved region of the FOG-2 UTR
Several groups have developed algorithms to predict microRNA
target sites within the 39 UTRs of vertebrate mRNAs [11,23,24].
One of these algorithms, PicTar (http://www.pictar.org), predict-
ed that the entire mouse FOG-2 39 UTR contains target sites for
34 different microRNAs. Due to the large number of miRNAs
predicted to target the FOG-2 39 UTR, we utilized a miRNA
microarray to first identify those miRNAs that are highly
expressed in the murine heart. An analysis of the miRNAs that
are predicted to target the FOG-2 UTR demonstrated that miR-
130a was the most highly expressed (Fig. 1A). Further, with the
continued improvement in quality and quantity of the genomic
sequences available from many diverse organisms, it was possible
for us to identify FOG-2 gene homologues from distantly related
species. An alignment of the FOG-2 39 UTRs from human,
mouse, rat, dog, cow, chicken, and zebrafish at the predicted miR-
130a target site is shown in figure 1B. We found a high degree of
sequence conservation at this site in species from human to
chicken with complete identity of the ‘‘seed’’ sequence, critical for
microRNA binding. However, this conservation in the seed
sequence is lost in the zebrafish fog2a gene (see Discussion). Given
its cardiac expression and target site conservation, miR-130a is an
attractive candidate as a potential regulator of FOG-2 mRNA
translation and thus is the focus of the remainder of this report.
To confirm that miR-130a was indeed expressed in the heart,
we performed northern analysis on total RNA from several
different adult mouse tissues using a radiolabeled probe specific to
miR-130a (Fig. 1C). As can be seen, miR-130a is predominately
expressed in the heart and lung, with lower amounts in the kidney.
FOG-2 mRNA is predominately expressed in the heart, brain, and
gonads in the adult, with lower levels in liver and lung [22]. Thus,
expression of miR-130a and FOG-2 overlaps in the heart and lung
and suggests that in these tissues miR-130a might modulate
translation of the FOG-2 message. To examine expression of miR-
130a in the developing heart, we took a PCR-based approach
given the small amount of tissue available for RNA preparation at
these early time points in development. Quantitative RT-PCR
performed with RNA prepared from hearts at embryonic day
11.5, 13.5, 15.5, neonatal (P0), and adult revealed the highest
levels of miR-130a expression at birth with levels approximately 3-
fold greater compared to the adult heart (compare columns 4 & 5,
Fig. 1D). This result demonstrates that miR-130a is present in the
embryonic heart and regulated in a dynamic pattern throughout
heart development. To determine FOG-2 protein levels during
heart development, we performed western analysis using an anti-
FOG-2 antibody on whole heart lysates from hearts at embryonic
day 10.5, 12.5, 14.5, 16.5 and from neonatal hearts (Fig. 1E).
These results reveal that FOG-2 protein levels are also
dynamically regulated during heart development, with peak levels
occurring at embryonic day 16.5 and diminishing in the neonate.
Interestingly, as miR-130a levels peak in the neonate, FOG-2
protein levels decline (Fig. 1F). Though several factors may
contribute to the dynamic pattern of FOG-2 protein expression
during development, these results are consistent with the notion
that miR-130a may play a role in regulating FOG-2 protein levels.
Translational inhibition via the FOG-2 39UTR
As a first step in determining the relevance of the 39 UTR of
FOG-2 for translational regulation, we generated a reporter
construct in the vector pRL (Fig. 2A). The pRL vector contains the
CMV promoter driving expression of an mRNA encoding
luciferase and an SV40 polyadenylation signal. We generated a
parallel construct in which the complete 39 UTR of murine FOG-
2 replaced the SV40 polyadenylation signal. The 39UTR of FOG-
2 contains a transcriptional terminator and polyadenylation site
and thus will allow proper processing of the mRNA. We then
transfected these constructs into NIH 3T3 fibroblasts, since it had
been previously shown that this cell line expresses miR-130a [25].
Forty-eight hours after transfection, fibroblasts were harvested and
assayed for luciferase expression. The results demonstrate that
fibroblasts transfected with the FOG-2 39 UTR construct showed
a 5.2-fold lower level of luciferase activity than that of the SV40
UTR construct (Fig. 2B, p,0.0001). To determine if the decrease
in luciferase activity was due to decreased message stability or
translational inhibition, we performed northern analysis using the
luciferase coding region as a probe. We found that luciferase
mRNA levels were higher in fibroblasts transfected with FOG-2-
UTR construct, indicating that the observed decrease in luciferase
activity in fibroblasts transfected with the FOG-2-UTR construct
was due to translational inhibition of the message rather than
decreased message stability (Fig. 2C).
MicroRNA-130a acts through the conserved site in the
FOG-2 UTR to mediate translational inhibition
To demonstrate the importance of the putative miR-130a
binding site within the FOG-2 39UTR for mediating translational
repression, we generated a reporter construct with a mutation of
the predicted binding site in the FOG-2 39 UTR (Fig. 3A). When
transfected into NIH 3T3 fibroblasts, disruption of this site (DA)
resulted in a 3.3-fold increase in luciferase activity (p,0.0001,
Fig. 3B). Northern analysis confirmed that this increase was not
due to an increase in mRNA stability, as message levels were
identical in both samples (Fig. 3C). This result suggests that this
site is required for UTR-mediated translational repression in
fibroblasts. To test if this site was also inhibiting translation of
FOG-2 in cardiomyocytes, we transiently transfected primary
neonatal cardiomyocytes with our reporter constructs containing
luciferase fused to the FOG-2 39UTR or to the UTR with the
microRNA target site disrupted (DA). The results shown in
figure 3D indicate a 2.9-fold increase in translation upon removal
of the microRNA target site (p,0.0001), suggesting the impor-
tance of this site for translational regulation of FOG-2 expression
in cardiomyocytes.
To demonstrate that miR-130a is required to mediate
translational repression via site A in the FOG-2 39 UTR, we took
two approaches. First, we took advantage of the ability of 29-O-
MiR-130a Regulation of FOG-2
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[26,27]. We designed a 29-O-methyl oligonucleotide to specifically
block miR-130a and co-transfected it along with our FOG-2 39
UTR reporter constructs into 3T3 fibroblasts. As expected, the
anti-miR-130a 29-O-methyl oligonucleotide had no effect on the
translational efficiency of the reporter with a mutation of the A site
(compare columns 4 & 5, Fig. 3E). In contrast, translational
repression of the reporter construct was relieved in a dose-
dependent fashion with the addition of increasing amounts of anti-
miR-130a 29-O-methyl oligonucleotide, resulting in luciferase
levels that were equivalent to those seen with the mutated A site in
the FOG-2 UTR (compare columns 3 & 4, Fig. 3E). These
observations strongly suggest that miR-130a is acting through the
A site of the FOG-2 39UTR to mediate translational repression.
We also used a gain of function approach to demonstrate miR-
130a’s role in mediating translational repression of FOG-2. As a
Figure 1. MicroRNA-130a is expressed in the heart. In (A), microarray analysis of microRNAs predicted to target the 39 UTR of FOG-2. Signal
intensity was taken as the mean of 8 probe sets and normalized to U6snRNP. In (B), an alignment of the predicted miR-130a target site in the FOG-2 39
UTR from several different species as predicted by MicroRNA.org. Shaded boxes indicate bases pairing with miR-130a. In (C), northern analysis of
100 mg total RNA from different adult mouse tissues using a probe specific for miR-130a. Ribosomal RNA is shown as a loading control below. In (D),
quantitative RT-PCR performed on RNA from pooled embryonic hearts at days 11.5, 13.5, 15.5, as well as neonatal and adult hearts. Results are
normalized to GAPDH expression levels (n=6). ‘*’ indicates a statistically significant difference (p,0.02) compared to adult. In (E), western analysis of
embryonic hearts during development using an anti-FOG-2 antibody (top panel) or Lamin B (as a control for equal protein loading, bottom panel). In
(F), graph of relative levels of miR-130a compared to FOG-2 protein levels during cardiac development.
doi:10.1371/journal.pone.0006161.g001
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not express miR-130a. Using northern analysis, we found that the
COS-7 monkey kidney fibroblast cell line does not express
detectable levels of miR-130a (Fig. 4A). We then tested our
reporter constructs containing the FOG-2 39UTR or the UTR
with the A site disruption in this cell line. As can be seen in
Figure 4B, the wild-type and DA constructs produced no
significant difference in luciferase activity, consistent with the
notion that miR-130a acts through the A site and that in the
absence of miR-130a, deletion of this site has no effect on the
ability of the UTR to modulate translational efficiency. To express
miR-130a in COS-7 fibroblasts, we engineered a mammalian
expression vector containing the CMV promoter driving expres-
sion of the miR-130a precursor stem loop structure (Fig. 4C).
Upon expression, this precursor is recognized and processed by
the miRNA processing enzymes Drosha and Dicer to produce
mature miR-130a. This strategy has been used in the past to
develop efficient expression vectors for other miRNAs [28,29]. We
tested the effectiveness of this strategy using northern analysis of
transiently transfected COS-7 fibroblasts. As shown in figure 4D,
this vector programmed expression of miR-130a in COS-7 cells in
a dose-dependent fashion. To test if expression of miR-130a would
repress translation of our reporter construct containing the FOG-2
39 UTR, we co-transfected COS-7 fibroblasts with our miR-130a
expression vector and our FOG-2 UTR reporter. As shown in
figure 4E, the addition of miR-130a to COS-7 fibroblasts inhibited
luciferase translation by 5264% (p,0.0001). Not surprisingly,
addition of miR-130a did not significantly alter luciferase activity
resulting from constructs with the altered target site (DA, columns
3 and 4, figure 4E). Taken together with the loss of function
experiments described above, these results demonstrate that miR-
130a targets the FOG-2 39 UTR to inhibit mRNA translation.
Overexpression of microRNA-130a in embryonic
cardiomyocytes results in structural heart defects
As we have shown previously, FOG-2 deficient mice die at
approximately embryonic day 13.5 due to multiple cardiac defects
that include ventricular septal defects and ventricular wall
hypoplasia [18,19]. It was our hypothesis that overexpression of
miR-130a in the embryonic heart would lead to similar defects by
inhibiting translation of FOG-2 mRNA. To study the effect of
miRNA-130a on cardiac development, we generated transgenic
mice with expression of the miR-130a precursor driven by the b-
MHC promoter. This promoter has been previously shown to
direct high-level expression in cardiomyocytes beginning at
embryonic day 9 [30]. Due to the lethality of FOG-2 deficient
mice at embryonic day 13.5, we suspected that transgenic over-
expression of miR-130a might also lead to embryonic lethality and
thus we would be unable to establish a viable transgenic line.
Indeed, of 40 live born pups examined, only 2 were transgenic
(5%), while the transgenic rate of embryonic day 13.5 embryos was
approximately 20%, suggesting a partial embryonic lethality of
transgenic embryos. Further, the 2 live born transgenic pups were
found not to express increased levels of miR-130a in their hearts
(data not shown), suggesting that these animals survived because
the transgene had been silenced in these animals, perhaps due to
integration site effects. Therefore, we chose instead to analyze our
miR-130a transgenics as F0 lines between embryonic days 13.5 to
14.5 of development. As a first step, we harvested transgenic
embryos at embryonic day 13.5 and isolated total RNA to perform
quantitative RT-PCR to confirm increased expression of miR-
130a. We found that compared to wild type littermates, 75% of
bMHC-miR-130a transgenic embryos displayed a significant
increase in miR-130a expression (Fig. 5A). Not surprisingly, the
level of increased expression varied between transgenic embryos
from 9 to 42 fold, likely due to integration site and copy number
differences. Of note, one of the four transgenic embryos examined
did not express significantly higher levels of miR-130a, consistent
with our observation of live born transgenic pups as described
above. To demonstrate the effect of miR-130a overexpression on
FOG-2 protein levels, we performed western analysis of bMHC-
miR-130a transgenic hearts using an anti-FOG-2 antibody. Three
of four hearts examined showed significantly reduced FOG-2
protein levels (Fig. 5B). Further, quantitation of protein levels
found that FOG-2 was reduced by 75 to 80% in half of the
embryos examined (Figure 5C). These results support the
hypothesis that translation of FOG-2 mRNA is regulated by
miR-130a in cardiomyocytes in vivo.
As a final step in our characterization of miR-130a transgenic
embryos, we performed histologic and echocardiographic analysis
of transgenic hearts at embryonic day 13.5 to 14.5. At embryonic
day 13.5, we observed morphologic defects in the hearts in 5 of 9
embryos examined (i.e., 9 independent lines). At embryonic day
14.5, we observed morphologic defects in 4 out of 5 transgenic
embryos examined (i.e., an additional 5 independent lines). At
both embryonic day 13.5 and 14.5, the left and right ventricular
free wall compact zone of transgenic hearts was thin when
compared to hearts of non-transgenic littermates. At embryonic
day 14.5, the left ventricular wall compact zone of affected hearts
was on average 2 to 3 cells thick, while that of wild-type littermates
was 15 to 18 cells thick (Fig. 5F & G). To evaluate the functional
Figure 2. The 39 UTR of FOG-2 inhibits mRNA translation. In (A),
a schematic of the expression vector pRL and its derivative containing
the FOG-2 39UTR in place of the SV40 polyadenylation sequence. In (B),
NIH 3T3 fibroblasts were transfected with the constructs shown above
along with pVRbgal. Forty-eight hours post transfection, cell lysates
were assayed for luciferase activity and normalized to b-galactosidase
activity. Results reported are the mean6S.E.M. (n=11). In (C), northern
analysis of 20 mg total RNA from transfected fibroblasts from (B) using a
probe specific to the luciferase coding region (above) or b-galactosi-
dase (below). ‘*’ indicates a statistically significant difference
(p,0.0001).
doi:10.1371/journal.pone.0006161.g002
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we used fetal echocardiography (Fig. 5H). At embryonic day 14.5,
transgenic embryos were found to have a reduced fractional
shortening (24% vs. 50%, p,0.0001) and increased left ventricular
end-diastolic diameter (1.15 mm vs. 0.79 mm, p,0.0001), dem-
onstrating severe left ventricular dysfunction in transgenic embryos
likely secondary to the thin ventricular compact zone. Histologic
analysis also revealed that the developing heart valves were normal
in appearance and there was no mal-alignment of the great vessels
of the outflow tract. However, in 4 of the 5 transgenic hearts
examined at embryonic day 14.5, a membraneous ventricular
septal defect was present (arrow, Fig. 5E), while none of non-
transgenic littermates examined had a ventricular septal defect.
The thin compact zone and ventricular septal defect are similar to
those seen in FOG-2 deficient hearts, providing further support to
the notion that miR-130a may play a role in the regulation of
Figure 3. The miR-130a target site in the FOG-2 39UTR is required for translational repression. In (A), a schematic of the constructs used
to evaluate the function of the conserved region of the FOG-2 39 UTR. In (B), NIH 3T3 fibroblasts were transfected with the constructs shown above
along with pVRbgal. Forty-eight hours post transfection, cell lysates were assayed for luciferase activity and normalized to b-galactosidase activity.
Results reported are the mean6S.E.M. (n=8). In (C), northern analysis of 10 mg total RNA from transfected fibroblasts from (B) using a probe specific
to the luciferase coding region (above) or b-galactosidase (below). In (D), primary neonatal cardiomyocytes were transfected with pVRbgal and a
luciferase reporter containing the 39UTR of FOG-2 or the DA3 9UTR mutation. Forty-eight hours after transfection, cells were assayed for luciferase and
b-galactosidase activity. Results are reported as the mean normalized luciferase activity6S.E.M. (n=20). In (E), NIH 3T3 fibroblasts were transfected
with a luciferase reporter containing the 39 UTR of FOG-2 (columns 1–3) or the DA mutation (columns 4 & 5) in the absence (columns 1 & 4) or
presence of increasing amounts of 29-O-methyl oligonucleotide (columns 2, 3, 5). Forty-eight hours post transfection, cell lysates were assayed for
luciferase activity and normalized to b-galactosidase activity. Results reported are the mean6S.E.M. (n=7). ‘*’ indicates a statistically significant
difference (p,0.01 )
doi:10.1371/journal.pone.0006161.g003
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translation.
Discussion
The regulation of protein translation by miRNAs is an emerging
field that will likely have a significant impact on aspects of
developmental biology and cancer. In this report, we have
demonstrated that the 39 UTR of FOG-2 contains an evolution-
arily conserved region that regulates translational efficiency in a
miR-130a-dependent fashion. While many plant messages target-
ed by miRNAs are cleaved and degraded, it is thought that most
vertebrate miRNAs function through translational inhibition of
their target mRNAs [4]. Our results are consistent with this
notion, although do not rule out that miR-130a may also target
other messages for degradation instead of translational inhibition
as seen with the FOG-2 39UTR. The 3.3-fold miR-130a-
dependent translational repression seen on the FOG-2 39 UTR
(Fig. 3) is comparable to what has been reported for other
vertebrate UTRs examined to date [11,31,32,33]. MiR-143 has
been shown to inhibit ERK5 mRNA translation 2-fold through a
site in its 39 UTR, miR-20a inhibits translation of the E2F1
Figure 4. Overexpression of miR-130a inhibits translation of mRNA containing the 39UTR of FOG-2. In (A), northern analysis using 20 mg
total RNA from COS-7 or NIH 3T3 cell lines with a probe specific for miR-130a. Ribosomal RNA is shown below as a loading control. In (B), COS-7
fibroblasts were transfected with a luciferase reporter containing the 39 UTR of FOG-2 (column 1) or the DA mutation (column 2) along with pVRbgal.
Forty-eight hours post transfection, cells were assayed for luciferase and b-galactosidase activity. Results report the mean normalized luciferase
activity6S.E.M. (n=12). Shown in (C) is a schematic of the miR-130a expression construct. In (D), northern analysis using a probe specific for miR-130a
and 20 mg total RNA from COS-7 fibroblasts transfected with increasing amounts of the miR-130a expression construct shown in (C). Ribosomal RNA
is shown below as a loading control. In (E), COS-7 fibroblasts were transfected with a luciferase reporter containing the 39 UTR of FOG-2 (columns 1 &
2) or the DA mutation (columns 3 & 4) in the absence (columns 1 & 3) or presence (columns 2 & 4) of the miR-130a expression construct. Forty-eight
hours post transfection, cell were assayed for luciferase activity. Results reported are the mean6S.E.M. (n=12); ‘*’ indicates statistically significant
decrease in activity (p,0.001).
doi:10.1371/journal.pone.0006161.g004
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Myotrophin mRNA 2-fold. The mechanism of translational
repression mediated by miRNAs is currently unclear, but is an
area of active research interest.
MicroRNA-130a was first cloned from mouse cerebellum and
subsequently identified in mouse embryonic stem cells [25,34].
Northern analysis has confirmed expression of miR-130a in mouse
embryonic fibroblasts and both human and mouse ES cells as well
as murine NIH 3T3 fibroblasts and mouse lung [25,35,36].
Consistent with these results, we have shown that miR-130a is
expressed in a tissue-restricted fashion, with highest levels in the
heart and lung. Other miRNAs have been described to have a
tissue-restricted pattern of expression including miR-1, expressed
in the heart and skeletal muscles, and miR-375, expressed solely in
pancreatic islets [31,34,37]. It is likely that as more miRNAs are
characterized, many will have a tissue or developmentally
restricted pattern of expression.
It is possible that other miRNAs also target the FOG-2 39UTR.
Indeed, the PicTar algorithm has identified 34 different micro-
RNAs that may target FOG-2 (see Fig. 1). It is possible that some
of these microRNAs may also modulate FOG-2 translation in
cardiomyocytes or in other cell types. Thus, it is likely that the
combinatorial effects of many different microRNAs acting in
concert on a specific UTR may provide the means to finely
regulate protein levels within various cells types and at different
stages of development.
As summarized in a number of excellent reviews, there is
growing evidence that miRNAs play a role in regulating
cardiovascular development [38,39]. Given our observation that
miR-130a expression is dynamically regulated in the heart during
embryonic development, miR-130a may also play a role in
regulating cardiac development, at least in part by translational
regulation of FOG-2, mediated through a conserved site located in
the FOG-2 39UTR. In addition to targeting FOG-2, miR-130a
also likely targets other genes involved in heart development.
Thus, we cannot rule out the possibility that translational
inhibition of other targets in the developing heart by miR-130a
may also contribute to the phenotype we have observed in our
miR-130a transgenic embryos.
As described in the Results section, only about two-thirds of our
transgenic embryos have a discernable cardiac phenotype. This
may be explained in part by approximately 25% of our F0
transgenic embryos not expressing significantly increased levels of
miR-130a (Fig. 5A). The lack of expression of a transgene is often
seen in the generation of any transgenic mouse line and is believed
to be due to silencing effects of the site of transgene integration. In
addition, another 25% of our transgenic embryos expressed levels
of miR-130a that were sufficient to only decrease FOG-2 protein
levels by less than 50%. Since mice heterozygous for a disruption
in the FOG-2 gene do not have any cardiac phenotype [18] and
only express 50% of normal FOG-2 levels (G. K. and E. S.,
unpublished observations), it is likely that transgenic mice with low
level miR-130a expression may also not develop cardiac
malformations due to only modest reductions in FOG-2 protein
levels.
During cardiac development, FOG-2 is expressed in the
myocardium, endocardium, and epicardium. Targeted disruption
of the FOG-2 gene results in embryos with hyperplastic
endocardial cushions, thin ventricular walls, and ventricular and
atrial septal defects [18]. In the miR-130a transgenic embryos,
FOG-2 levels should only be reduced in cardiomyocytes, since the
b-MHC promoter used to drive expression of miR-130a in our
transgenic mice is not active in the developing endocardial
cushions or epicardium [30]. Thus, it is not surprising that the
Figure 5. Cardiac overexpression of miR-130a results in
decreased FOG-2 expression and a thin ventricular myocardial
wall. In (A), expression of miR-130a as determined by quantitative RT-
PCR on four wild type (WT) and four transgenic hearts (TG-1 thru 4) at
embryonicday13.5.Resultsrepresentthemean6S.E.M.ofthreeseparate
experiments performed in duplicate. ‘*’ indicates statistically significant
difference from wild-type, p,0.002. In (B), western analysis of wild type
(WT) and transgenic hearts (TG-5 thru 8) using an anti-FOG-2 antibody.
Western analysis of Lamin B was used as a control for equal protein
loading. Quantitation of this blot is shown in (C), with wild type levels of
FOG-2 set to 100%. In (D - G), transverse sections of embryonic day 14.5
hearts from wild type (D, F) and b-MHC-miR-130a transgenics (E, G)
stained with hematoxylin and eosin. Note the ventricular septal defect
(arrow, E) and the thin compact zone of ventricular myocardium
(arrowheads, F compared to G) seen in the transgenic embryos. In (H),
echocardiographic determination of left ventricular fractional shortening
(left panel) and left ventricular end diastolic diameter (right panel) in
embryonic day 14.5 transgenic and non-transgenic embryos. ‘*’ indicates
a statistically significant difference (p,0.0005).
doi:10.1371/journal.pone.0006161.g005
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phenotype of the FOG-2
2/2 embryos. However, the thin compact
zone seen in the miR-130a transgenic mice is similar to that seen
in the FOG-2 deficient mice, suggesting that this phenotype may
be due to reduced FOG-2 levels. It is currently unclear how
reduced cardiac FOG-2 levels lead to a thin ventricular wall, but
the results presented in this report suggest that it is due to the loss
of FOG-2 specifically in cardiomyocytes, rather than the
endocardium or epicardium. The ventricular septal defect seen
in the miR-130a transgenics may be due to the failure of the
myocardium in the proximity of the developing endocardial
cushions to send the appropriate signals to allow for the normal
maturation of the membraneous interventricular septum.
Finally, it is interesting that the miR-130a target site in the
FOG-2 UTR is highly conserved in species from chicken to
human, but is not conserved in the two zebrafish orthologues of
FOG-2, fog2a and fog2b [40]. The loss of conservation of this site in
the zebrafish FOG-2 genes may be explained by the lack of
expression of these genes in the developing heart, in contrast to
their orthologues in higher vertebrates. This suggests that miR-
130a may have a distinct function in higher vertebrates during
heart development as compared with its function in zebrafish. A
direct demonstration of miR-130a’s function during development
must await the generation of mice with a targeted disruption of the
miR-130a gene.
Materials and Methods
Plasmids
pVRbGal, a plasmid that expresses the LacZ gene under the
control of the CMV promoter, has been previously described [41].
pRL-CMV was obtained from Promega (Madison, WI). The
murine FOG-2 39 UTR (4026–4056 bp of Genbank accession
number AF118845) was amplified from pcDNA-FOG-2 [22] using
PCR and the primers 59-GCGTCTAGAACTAACTGAGT-
TACT and 59-GCGGATCCCCAACAATTTGGAATT. This
1009 bp fragment was cloned into the XbaI/BamHI site of
pRL-CMV after the SV40 polyadenylation sequence had been
removed. The DA construct was generated by using PCR-based
mutagenesis of the 1009 bp FOG-2 UTR and the primers 59-
AGCTACTATAGTGTCCGTATCGCTAGATGCACACAAG-
AACTATACAATCA and 59-GTTCTTGTGTGCATCTAGC-
GATACGGACACTATAGTAGCTTTTAAAGAAA. This gen-
erated a FOG-2 UTR with a 20 bp mutation in the predicted
miR-130a binding site. The resulting fragment was cloned into the
XbaI/BamHI site of pRL-CMV as above. The miR-130a
expression construct was generated using PCR to amplify a
467 bp fragment encoding the miR-130a precursor from mouse
genomic DNA with the primers 59CACTCGAGCTCTGGA-
CAGGTCTACAAAAATGGand 59-CATTGCGGCCGCCC-
TTGAGAAGTGTCAAATGATGG. This fragment was cloned
into the NotI/XhoI sites of pcDNA3 (Invitrogen, Carlsbad, CA).
The transgenic miR-130a over-expression construct, pb-MHC-
miR-130a, was generated by inserting the miR-130a genomic
fragment described above into a plasmid containing 5.6 kb of the
murine b-MHC promoter and the human growth hormone
polyadenylation signal [42]. All constructs were verified by DNA
sequencing.
Cell culture and Transfections
Primary culture of rat neonatal cardiocytes were prepared as
previously described [43] and plated into rat tail collagen-coated
12-well plates. Seventy-two hours after plating, cardiocytes were
transfected with 650 ng luciferase reporter plasmid, 350 ng
pVRbGal, and 3 ml Fugene6 in SMEM to a total volume of
100 ml. Cells were incubated for 3 hours at 37uC, 5% CO2 and
then 2 mls growth media was added. Cardiomyocytes were
transfected in five independent experiments performed in
quadruplicate. COS-7 and NIH 3T3 fibroblasts were transfected
using Superfect (Qiagen, Valencia, CA) with 200 ng pVRbGal,
2 mg luciferase reporter plasmid, 0–2 mg of the anti-miR-130a 29-
O-methyl oligonucleotide (59-GCCCUUUUAACAUUGCA-
CUC) and pcDNA3 to a total of 5 mg DNA as described
previously [44]. All fibroblast transfections were carried out in
triplicate in 3 to 4 independent experiments.
Luciferase and b-galactosidase assays
Forty-eight hours after transfection, cells were harvested and
lysed in 300 ml of Renilla 16 Reporter Lysis buffer (Promega)
following manufacturer’s instructions. Luciferase activity was
measured using 20–75 ml of this lysate with 100 ml luciferin using
aT D 220/20 luminometer. b-galactosidase activity was measured
in these lysates as previously described [44]. Relative luciferase
activity was calculated as the raw luciferase activity divided by the
b-galactosidase activity.
Northern Analysis
Total RNA was isolated from cell lines or adult mouse tissues
using the TRIZOL reagent (Invitrogen) according to the
manufacturer’s instructions. For northern analysis of transfected
cell lines, 10 mg of total RNA was resolved on 1.2% denaturing
agarose gel electrophoresis followed by transfer to a Hybond N+
membrane (Amersham Biosciences, Piscataway, NJ). The mem-
brane was hybridized to a
32P-labeled fragment of the luciferase
cDNA (bp 836–2005 of pRL-CMV) or b-galactosidase cDNA as
described previously [22]. For northern analysis of miR-130a,
100 mg of total RNA was resolved by 15% denaturing polyacryl-
amide gel electrophoresis and then transferred to a Hybond N+
membrane using a semidry transfer apparatus (Bio-Rad, Hercules,
CA) at 300 mA for 90 mins. Following transfer, this membrane
was crosslinked and prehybridized at 35uC in Hyb buffer (50%
formamide, 56SSPE, 1% SDS, 5xDenhardt’s solution, and
33 mg/ml denatured herring sperm DNA) for 1–2 hours. Subse-
quently it was hybridized with 20 ng/ml of a
32P-radiolabeled
LNA oligonucleotide complementary to miR-130a( 59-
GCCCTTTTAACATTGCACTC) in Hyb buffer at 35uC
overnight. The following day the membrane was washed twice
for 15 mins with 26SSC, 0.1% SDS at 35uC and then exposed to
film overnight.
MicroRNA Microarray
Total RNA was prepared from two hearts of 8-week old CD-1
mice using TRIZOL reagent (Invitrogen) according to the
manufacturer’s instructions. One microgram of total RNA from
each preparation was labeled with Hy3 using the miRCURY LNA
microRNA Power labeling kit (Exiqon) and then hybridized to
miRCURY LNA microRNA array v.10.0 (Exiqon). Array
scanning was performed with a GenePix 4000B scanner.
Western Analysis
Embryonic day 13.5 hearts were harvested and 50 mg of total
cell lysates were resolved by 7% SDS-PAGE followed by western
transfer to a nitrocellulose membrane. The membrane was
blocked with Blotto (10 mM Tris, pH 7.5, 140 mM NaCl,
0.05% Tween-20, 5% powdered milk) for 1 hour at room
temperature, followed by incubation with a 1:1000 dilution of
anti-FOG-2 rabbit polyclonal antibody (Santa Cruz, M-247) or a
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Blotto. The membrane was washed with TBST (10 mM Tris,
pH 7.5, 140 mM NaCl, 0.05% Tween-20), incubated for 1 hour
with a 1:5000 dilution of goat anti-rabbit antibody conjugated to
horseradish peroxidase. The blot was then washed extensively and
developed using a commercially available kit (ECL-plus, GE
Healthcare, Piscataway, NJ). Quantitation was performed by
densitometry using a Molecular Dynamics STORM 860 Phos-
phoimager and intensity of FOG-2 signal was normalized to that
of Lamin B to control for variations in protein loading.
Quantitative PCR
Total RNA was isolated as previously described. 10 ng of total
RNA was used to perform reverse transcription using the
TaqManH microRNA assays kit and MicroRNA Reverse
Transcription kit (Applied Biosystems) according to the manufac-
turer’s instructions. PCR amplification was then performed using
TaqManH 2X Universal PCR Master Mix (Applied Biosystems).
Data analysis was performed according to the technique described
by Tichopad et al. and normalized to results obtained with primers
specific to GAPDH. Results represent three independent exper-
iments performed in duplicate (n=6) and are reported as the
mean6S.E.M.
Transgenic Mouse Generation
All mice were cared for and experiments performed in
accordance with the policies of the University of Chicago Animal
Care and Use committee. Pronuclear injections were performed
into CD-1 or C57BL/6 oocytes using a 10 kb fragment of pb-
MHC-miR-130a containing 5.6 kb of the b-MHC promoter
driving expression of miR-130a. Thirteen to fourteen and a half
days following injection, embryos were harvested and genomic
DNA was isolated from embryonic yolk sac. A PCR-based assay
using primers specific for the b-MHC-miR130a transgene (59-
AAGATTGTGCCACTGCACTCCAGC and 59-CCTCAG-
CATCACTGCATTTTCTCC) was used to identify transgenic
embryos. Embryos were fixed in 10% formalin at 4uC, then
dehydrated with washes of increasing concentrations of ethanol
(50%, 70%, 95% and 100%). Embryos were embedded in
paraffin, sectioned, and stained with hematoxylin and eosin.
Images were obtained using a Zeiss Axiophot microscope.
Echocardiography
We performed fetal echocardiography in mice using inhaled
isoflurane (,1%) for anesthesia, delivered via nose cone. The
abdominal hair was removed from the pregnant dam with a
topical depilatory agent. Body temperature was maintained using
a heated imaging platform and warming lamps. The embryos were
imaged in utero with a VisualSonics Vevo 770 machine using a
30 MHz high-frequency transducer. Two-dimensional images
were recorded in approximately the parasternal long- and short-
axis projections with guided M-mode recordings at the midven-
tricular level in both views. Left ventricular internal dimensions at
diastole and systole (LVIDd and LVIDs, respectively) were
measured in at least three beats from each projection and
averaged. Left ventricular fractional shortening [(LVIDd –
LVIDs)/LVIDd] was calculated from the M-mode measurements.
Relative positions of individual embryos within the uterus were
noted and following echocardiography, all embryos were harvest-
ed for genotype determination as described above.
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